Recent Analysts' Ratings Changes for China Biologic Products

Recent Analysts' Ratings Changes for China Biologic Products


5/15/2018 - China Biologic Products was upgraded by analysts at Zacks Investment Research from a "strong sell" rating to a "hold" rating. According to Zacks, "China Biologic Products, Inc., through its indirect majority-owned subsidiary, is principally engaged in the research, development, production, manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China.



from Biotech News